Cases & Deals

  • Home
  • Practices
  • BioMarin resolves patent infringement claims against Par Pharmaceutical related to Kuvan®

Share

BioMarin resolves patent infringement claims against Par Pharmaceutical related to Kuvan®

April 2017

Client(s) BioMarin Pharmaceutical Inc.

Jones Day client BioMarin Pharmaceutical, Inc. successfully resolved a patent infringement action against Par Pharmaceutical, Inc. relating to the defendant's submission of an Abbreviated New Drug Application to the FDA seeking approval of a generic version of Kuvan® (sapropterin dihydrochloride), the only FDA-approved treatment to reduce blood phenylalanine levels in persons with BH-4 responsive phenylketonuria (PKU).

BioMarin Pharmaceutical Inc. et al. v. Par Pharmaceutical, Inc., Case No. 3:15-cv-01706 (D.N.J.)

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.